Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:11:40时区推断·⟳ 抓取 20:15:00·⚡ 决策 07-22 20:23:53 +8m53s·96.9 天前
Arrowhead降脂药plozasiran两项III期sHTG试验达主要和次要终点
plozasiran在SHASTA-3和SHASTA-4中位甘油三酯降幅分别为79%和81%，安慰剂约27%，且无新增安全性事件。
📄 原文Seeking Alpha↗ 原文
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
Arrowhead Pharmaceuticals (ARWR) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran…
不做 Arrowhead Pharmaceuticals（ARWR.US）
临床数据利好成立，但原文已显示股价大幅反应，且扩适应症仍需sNDA和审评，当前不追。
不做 Ionis Pharmaceuticals（IONS.US）
竞品利空成立但IONS近20日已大跌且未核到可借券数据，不满足可执行做空红线。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 报道Arrowhead宣布plozasiran两项III期sHTG试验成功，且提到ARWR已涨18%、IONS跌近5%。市场反应:原文显示ARWR已大涨、IONS已下跌，说明核心反应已发生。
- FDA页面确认Redemplo已获批用于FCS，当前事件是向sHTG扩适应症的临床进展。
关键理由
- plozasiran在SHASTA-3和SHASTA-4中位甘油三酯降幅分别为79%和81%，安慰剂约27%，且无新增安全性事件。
- 公司计划年底前提交sNDA，若获批可从FCS扩展至更大的重度高甘油三酯血症人群。
- 同日报道已显示ARWR盘中/盘前大幅反应，IONS竞品压力已被市场即时交易。
主要风险
- 仍需年底提交sNDA并等待FDA审评，商业化增量从试验成功到收入兑现有较长时间差。
- IONS近20日已大跌约29.65%，竞品利空已部分反映且做空需要更强执行证据。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-22 · 影响 weakens
主要反向约束是仍需sNDA提交和审评，收入兑现不在短线窗口。
检索:ARWR plozasiran SHASTA-3 SHASTA-4 sHTG risks FDA sNDA commercialization 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,342 字
Arrowhead Pharmaceuticals (ARWR) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceridemia, hurting the shares of Ionis Pharmaceuticals (IONS), which is advancing a rival therapy.
California-based Arrowhead (ARWR) said that plozasiran, which is already available in the U.S. as Redemplo for familial chylomicronemia syndrome, the most serious form of sHTG, met all the key goals in its Phase 3 SHASTA-3 and SHASTA-4 trials.
Its shares added 18% in reaction, while Ionis (IONS), whose sHTG therapy olezarsen is currently under the FDA's priority review with a decision expected by June 30, lost nearly 5%.
Arrowhead (ARWR) said that plozasiran, as a subcutaneous injection, met the primary endpoint and all prespecified secondary endpoints in SHASTA-3 and SHASTA-4, causing median triglyceride reductions of 79% and 81% at month 12, respectively.
In comparison, patients on placebo witnessed a median triglyceride reduction of roughly 27%. There were no new safety events, and the incidence of overall treatment-emergent adverse events and related TEAEs was in line with plozasiran’s prior study data.
The company expects to submit a supplemental new drug application with the FDA before the end of this year, seeking a label expansion for the drug in the U.S. for sHTG.
California-based Arrowhead (ARWR) said that plozasiran, which is already available in the U.S. as Redemplo for familial chylomicronemia syndrome, the most serious form of sHTG, met all the key goals in its Phase 3 SHASTA-3 and SHASTA-4 trials.
Its shares added 18% in reaction, while Ionis (IONS), whose sHTG therapy olezarsen is currently under the FDA's priority review with a decision expected by June 30, lost nearly 5%.
Arrowhead (ARWR) said that plozasiran, as a subcutaneous injection, met the primary endpoint and all prespecified secondary endpoints in SHASTA-3 and SHASTA-4, causing median triglyceride reductions of 79% and 81% at month 12, respectively.
In comparison, patients on placebo witnessed a median triglyceride reduction of roughly 27%. There were no new safety events, and the incidence of overall treatment-emergent adverse events and related TEAEs was in line with plozasiran’s prior study data.
The company expects to submit a supplemental new drug application with the FDA before the end of this year, seeking a label expansion for the drug in the U.S. for sHTG.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。